Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved full

Medical Reports Third Quarter 2024 Results and Other Exciting Events

FDA approval to begin pivotal trial of

fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear

implant are two of the exciting developments for the growing company

WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy

Medical , Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing

devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events.

"The progress and accomplishments of

late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing

devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim fully implanted cochlear implant

("Acclaim CI"). Second, we continue to make tremendous progress on obtaining meaningful reimbursement for our already FDA-approved

Esteem FI-AMEI. We continue to receive considerable support for the bipartisan bills that were introduced in both the House and the

Senate this year to change the way fully implanted active middle ear hearing devices classified by CMS. In addition, the American Medical

Association's CPT Editorial Panel has approved Category III CPT codes for totally implantable active middle ear hearing devices

for the first time. A significant step forward for our Esteem device. Ultimately, we continue to believe that our products are important

innovations for patients suffering from hearing loss and foresee a bright future for Envoy Medical," commented Brent Lucas, Envoy

Medical's Chief Executive Officer. "We look forward to updating shareholders on our progress as we initiate the trial for

the Acclaim device and as we progress with our reimbursement strategy for the Esteem device."."

Corporate Highlights from Q3 2024 and To Date

Financial Results for the Quarter Ended September 30, 2024

Net revenues were $56 thousand for the quarter ended September 30,

2024, a decrease of $24 thousand from $80 thousand for the same period in 2023. Net revenues were $183 thousand for the nine months ended

September 30, 2024, a decrease of $38 thousand compared to the previous period. Both decreases were due mainly to a reduction in the number

of battery replacement requests for Esteem implants received during the noted periods, and also as a result of supply chain issues.

R&D expenses increased $907 thousand from $1.9 million to $2.8

million for the three months ended September 30, 2024, and the nine-month results showed an increase of $1.8 million from $5.9 million

to $7.7 million for September 30, 2024. Both increases were due to costs associated with additional headcount and contractors across our

clinical and engineering departments in preparation for the pivotal clinical study for the Acclaim CI.

Sales and marketing expenses decreased by $5 thousand for the three

months ended September 30, 2024 as compared to the same period for 2023, although for the nine months ended September 30, 2024 increased

by $63 thousand compared to the same period in 2023. For the year to date results, increases in legal and professional fees to secure

insurance reimbursement for the Esteem FI-AMEI product were offset by reductions in headcount.

General and administrative expenses increased by $665 thousand to $1.7

million for the three months ended September 30, 2024, and the year-to-date results showed a $1.2 million increase over the prior year.

The increases are due primarily to increased legal and professional fees normally associated with being a publicly traded company and

other administrative expenses.

As of September 30, 2024, cash and cash equivalents were approximately

About the Fully Implanted Acclaim

We believe the fully implanted Acclaim Cochlear

Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a

sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe

to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for

adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the

Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational

device. Limited by Federal (or United States) law to investigational use.

About the Esteem Fully Implanted Active

Middle Ear Implant (FI-AMEI)

The Esteem fully implanted active middle ear

implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural

hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible

and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put

it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

Important safety information for the Esteem

FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find

Copies of the documents filed by Envoy Medical

with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

Forward-Looking Statements

This press release includes "forward-looking

statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform

Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project,"

"forecast," "intend," "will," "expect," "anticipate," "believe,"

"seek," "target" or other similar expressions that predict or indicate future events or trends or that are not

statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements

may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity,

plans and goals for future operational improvements and capital investments; the Acclaim CI being the first to market fully implanted

cochlear implant, the result of the clinical trial, the timing and results of clinical trials of the Acclaim CI, and the participation

of any institution in such trials; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible

or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's

current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances

that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not

guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject

to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class

A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index;

Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability

in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical

products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at

competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or

disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes

in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation;

legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the

application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately

protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts;

and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward

Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical

files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ

materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's

good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise

any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events

or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any

forward-looking statements, which are based only on information currently available to Envoy Medical.

Chief Financial Officer

CONSOLIDATED BALANCE SHEETS

thousands, except share and per share amounts)